MolDX: NRAS Genetic Testing

Coverage is limited to somatic NRAS testing of tumor tissue for metastatic colorectal cancer (mCRC) per NCCN v2.2016 to inform anti-EGFR therapy decisions. All other indications — including NRAS testing for melanoma, other tumor types, and germline testing for Noonan syndrome — are non-covered due to insufficient evidence of clinical utility.

"NRAS tumor tissue testing for somatic NRAS mutations is covered for patients with metastatic colorectal cancer (mCRC) to guide anti-EGFR therapy decisions per NCCN Guidelines (Version 2."

Sign up to see full coverage criteria, indications, and limitations.